Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp

Bullboard Posts

Post by jwalliscaon Nov 25, 2019 11:23am

140 Views

Post# 30389417

A.N. Other Example - Novartis

ASS_U_Me that the headlines, excitement and M&A continue on the ongoing progress in regenerative medicine...

This suggests that this rapidly heating up space puts Sernova and its POUCH in an enviable position.

We have seen where Medtronic (heavily diabetes focused) is looking for "Tuck-ins".

We saw Sanofi snack on Bioverativ for the Hemophilia exposure.

We saw the Vertex vortex of SEMMA (for the diabetes exposure)... well... Novartis was kind of involved in SEMMA before the Hasta La Vista Baby.

Two senior Novartis executives left Novartis to join SEMMA. One became CEO and the other became the Chief Medical Officer.
https://www.bizjournals.com/boston/news/2018/05/10/former-novartis-exec-to-lead-cambridge-diabetes.html

https://xconomy.com/boston/2018/12/18/david-lebwohl-leaves-novartis-for-chief-medical-post-at-semma/

I, for one, would have no issues with a bidding war should Sernova be (subjunctive case) so lucky.

jwall

Bullboard Posts

Changing Europe’s dependency on HREE from China